Hims & Hers Health (HIMS) is experiencing a severe decline in stock value following the FDA's announcement that the semaglutide shortage has been resolved. The company, which had benefited from selling discounted compounded versions of weight-loss drugs like Ozempic and Wegovy, can no longer guarantee its ability to continue those sales. The lack of FDA-sanctioned demand for its compounded drugs led to a 28% plunge in stock price, reflecting investor concern over a significant loss of revenue. Despite recent strong financial performance, the outlook for Hims & Hers has become increasingly uncertain due to this regulatory change.
Hims & Hers Health is facing significant challenges after the FDA announced the end of a semaglutide shortage, which jeopardizes their compounding drug sales.
Despite strong financial results, the end of the semaglutide shortage has caused Hims & Hers stock to plunge by 28%, cutting shares in half from their recent highs.
Collection
[
|
...
]